Noretreat wrote: "Typically a placebo is a sugar pill.  What we have been calling the "placebo" group for BOM is actually the current Standard of Care....much different from a sugar pill. Don only has 8 minutes to get a lot across on Nov 16th.  If he talks about placebo being one side of his forest graph, he is, in my view, making a mistake.  What he is comparing is "standard of Care" to "standard of Care plus Apabetalone. He needs to be as clear about this as possible.  His audience will not be as highly involved with the subject as we are."

Don will not be the one giving the late breaking presentation at AHA on Saturday November 16th (two weeks from today!!!). It will be given by Dr. Kausik Ray, the lead investigator and head of the Clinical Steering Committee for the BETonMACE trial. Everyone in attendance at AHA (or at least all of the clinical medicine literate ones) will know what standard of care is and means and know that BETonMACE is testing apabetalone on top of this standard of care. There will be zero confusion here. It sound like Don will be the one giving the pre-market webcast on Monday November 18th. But have no worries, it will be Dr. Ray presenting the Nov 16th late breaker. 

Here's a prior post and ESC 2019 poster and the BETonMACE design and rational paper (if you have access) summarizing the BETonMACE standard of care. Standard of care includes many drugs besides statins including diabetes, hypertension, and anti-platelet agents. These drugs include, but are not limited to, metformin, GLP-1R agonists, SGLT2 inhibitors, insulin, sulfonylureas, DPP4 inhibitors, beta blockers, ACE inhibitors, etc. 

BearDownAZ